LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.

    Rindi, Lorenzo Vittorio / Zaçe, Drieda / Braccialarghe, Neva / Massa, Barbara / Barchi, Virginia / Iannazzo, Roberta / Fato, Ilenia / De Maria, Francesco / Kontogiannis, Dimitra / Malagnino, Vincenzo / Sarmati, Loredana / Iannetta, Marco

    Drug safety

    2024  Volume 47, Issue 4, Page(s) 333–354

    Abstract: Introduction: Progressive multifocal leukoencephalopathy (PML) was first described among patients affected by hematological or solid tumors. Following the human immunodeficiency virus (HIV) epidemic, people living with HIV have represented most cases ... ...

    Abstract Introduction: Progressive multifocal leukoencephalopathy (PML) was first described among patients affected by hematological or solid tumors. Following the human immunodeficiency virus (HIV) epidemic, people living with HIV have represented most cases for more than a decade. With the diffusion of highly active antiretroviral therapy, this group progressively decreased in favor of patients undergoing treatment with targeted therapy/immunomodulators. In this systematic review and meta-analysis, the objective was to assess which drugs are most frequently related to PML development, and report the incidence of drug-induced PML through a meta-analytic approach.
    Methods: The electronic databases MEDLINE, EMBASE, ClinicalTrials.gov, Web of Science and the Canadian Agency for Drugs and Technologies in Health Database (CADTH) were searched up to May 10, 2022. Articles that reported the risk of PML development after treatment with immunomodulatory drugs, including patients of both sexes under the age of 80 years, affected by any pathology except HIV, primary immunodeficiencies or malignancies, were included in the review. The incidence of drug-induced PML was calculated based on PML cases and total number of patients observed per 100 persons and the observation time. Random-effect metanalyses were conducted for each drug reporting pooled incidence with 95% confidence intervals (CI) and median (interquartile range [IQR]) of the observation time. Heterogeneity was measured by I
    Results: A total of 103 studies were included in the systematic review. In our analysis, we found no includible study reporting cases of PML during the course of treatment with ocrelizumab, vedolizumab, abrilumab, ontamalimab, teriflunomide, daclizumab, inebilizumab, basiliximab, tacrolimus, belimumab, infliximab, firategrast, disulone, azathioprine or danazole. Dalfampridine, glatiramer acetate, dimethyl fumarate and fingolimod show a relatively safe profile, although some cases of PML have been reported. The meta-analysis showed an incidence of PML cases among patients undergoing rituximab treatment for multiple sclerosis (MS) of 0.01 cases/100 persons (95% CI - 0.08 to 0.09; I
    Conclusions: A higher risk of drug-related PML in patients whose immune system is not additionally depressed by means of neoplasms, HIV or concomitant medications is found in the neurological field. This risk is higher in MS treatment, and specifically during long-term natalizumab therapy. While this drug is still routinely prescribed in this field, considering the efficacy in reducing MS relapses, in other areas it could play a smaller role, and be gradually replaced by other safer and more recently approved agents.
    MeSH term(s) Male ; Female ; Humans ; Aged, 80 and over ; Natalizumab/adverse effects ; Leukoencephalopathy, Progressive Multifocal/chemically induced ; Leukoencephalopathy, Progressive Multifocal/epidemiology ; Canada ; Immunologic Factors/adverse effects ; Multiple Sclerosis/drug therapy ; HIV Infections/drug therapy
    Chemical Substances Natalizumab ; Immunologic Factors
    Language English
    Publishing date 2024-02-07
    Publishing country New Zealand
    Document type Meta-Analysis ; Systematic Review
    ZDB-ID 1018059-x
    ISSN 1179-1942 ; 0114-5916
    ISSN (online) 1179-1942
    ISSN 0114-5916
    DOI 10.1007/s40264-023-01383-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Doravirine/lamivudine/tenofovir disoproxil fumarate-induced hypertriglyceridemia in a newly diagnosed AIDS patient.

    Barchi, Virginia / Rindi, Lorenzo Vittorio / Iannazzo, Roberta / Massa, Barbara / De Simone, Giuseppe / Andreoni, Massimo / Sarmati, Loredana / Iannetta, Marco

    AIDS (London, England)

    2022  Volume 36, Issue 15, Page(s) 2231–2233

    MeSH term(s) Humans ; Lamivudine/adverse effects ; HIV Infections/drug therapy ; Fumarates/therapeutic use ; Acquired Immunodeficiency Syndrome/drug therapy ; Anti-HIV Agents/adverse effects ; Tenofovir/adverse effects ; Hypertriglyceridemia/chemically induced ; Hypertriglyceridemia/drug therapy ; Emtricitabine/therapeutic use
    Chemical Substances Lamivudine (2T8Q726O95) ; doravirine (913P6LK81M) ; Fumarates ; Anti-HIV Agents ; Tenofovir (99YXE507IL) ; Emtricitabine (G70B4ETF4S)
    Language English
    Publishing date 2022-08-23
    Publishing country England
    Document type Journal Article
    ZDB-ID 639076-6
    ISSN 1473-5571 ; 0269-9370 ; 1350-2840
    ISSN (online) 1473-5571
    ISSN 0269-9370 ; 1350-2840
    DOI 10.1097/QAD.0000000000003370
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: The Impact of Viral and Bacterial Co-Infections and Home Antibiotic Treatment in SARS-CoV-2 Hospitalized Patients at the Policlinico Tor Vergata Hospital, Rome, Italy.

    Di Lorenzo, Andrea / Campogiani, Laura / Iannetta, Marco / Iannazzo, Roberta / Imeneo, Alessandra / Alessio, Grazia / D'Aquila, Veronica / Massa, Barbara / Fato, Ilenia / Rindi, Lorenzo Vittorio / Malagnino, Vincenzo / Teti, Elisabetta / Andreoni, Massimo / Sarmati, Loredana

    Antibiotics (Basel, Switzerland)

    2023  Volume 12, Issue 9

    Abstract: Co-infections during COVID-19 may worsen patients' outcomes. This study reports the results of a screening assessing the presence of co-infections among patients hospitalized for SARS-CoV-2 infection in the Infectious Diseases-Ward of the Policlinico Tor ...

    Abstract Co-infections during COVID-19 may worsen patients' outcomes. This study reports the results of a screening assessing the presence of co-infections among patients hospitalized for SARS-CoV-2 infection in the Infectious Diseases-Ward of the Policlinico Tor Vergata Hospital, Rome, Italy, from 1 January to 31 December 2021. Data on hepatitis B and C virus, urinary antigens for legionella pneumophila and streptococcus pneumoniae, pharyngeal swab for respiratory viruses, QuantiFERON
    Language English
    Publishing date 2023-08-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2681345-2
    ISSN 2079-6382
    ISSN 2079-6382
    DOI 10.3390/antibiotics12091348
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV.

    Vergori, Alessandra / Cozzi Lepri, Alessandro / Cicalini, Stefania / Matusali, Giulia / Bordoni, Veronica / Lanini, Simone / Meschi, Silvia / Iannazzo, Roberta / Mazzotta, Valentina / Colavita, Francesca / Mastrorosa, Ilaria / Cimini, Eleonora / Mariotti, Davide / De Pascale, Lydia / Marani, Alessandra / Gallì, Paola / Garbuglia, AnnaRosa / Castilletti, Concetta / Puro, Vincenzo /
    Agrati, Chiara / Girardi, Enrico / Vaia, Francesco / Antinori, Andrea

    Nature communications

    2022  Volume 13, Issue 1, Page(s) 4922

    Abstract: In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/ ... ...

    Abstract In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm
    MeSH term(s) 2019-nCoV Vaccine mRNA-1273 ; Antibodies, Viral ; BNT162 Vaccine ; COVID-19/prevention & control ; COVID-19 Vaccines/immunology ; HIV Infections ; Humans ; Immunogenicity, Vaccine ; Middle Aged ; SARS-CoV-2
    Chemical Substances Antibodies, Viral ; COVID-19 Vaccines ; 2019-nCoV Vaccine mRNA-1273 (EPK39PL4R4) ; BNT162 Vaccine (N38TVC63NU)
    Language English
    Publishing date 2022-08-22
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-022-32263-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top